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The central role of dendritic cells (DC) in the immune sys-
tem and their unique potency to induce tumor-specific
killer and helper T cells has been demonstrated in numer-
ous studies and is today unequivocal. Therefore, DC-
based immunotherapy represents one of the most prom-
ising approaches to fight cancer and since the first vaccina-
tion study in 1996 numerous trials have been performed
with more than 30 DC-based vaccination trials published
only in the past 3 years. In principle, antigen can be deliv-
ered to DC by various strategies, but most commonly HLA
class I or II restricted peptides derived from defined tumor
antigens have been used. Because peptides can be readily
obtained in clinical grade quality, are easily standardized
and facilitate the immuno-monitoring during clinical tri-
als, they can still be considered as gold standard of DC
antigen loading.
Nevertheless, several issues concerning the use of peptide-
loaded DC still have to be addressed. In the present study
we carefully analyzed different parameters such as peptide
concentration, stability of HLA/peptide complexes on
immature (i-DC) versus mature-DC (m-DC) or antigen
competition in order to optimize the loading of DC with
HLA class I and II peptides.
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